Effects of rosiglitazone on contralateral iliac artery after vascular injury in hypercholesterolemic rabbits

Thrombosis Journal

Volumn 6, Issue , 2008, Pages

  França Neto, Olímpio Ribeiro ^a   Precoma, Dalton Bertolim ^a   Alessi, Alexandre ^a   Prim, Camila ^a   da Silva, Ruy Fernando Kuenzer Caetano ^a   de Noronha, Lucia ^a   Baroncini, Liz Andréa Villela ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COLLAGEN TYPE 1; COLLAGEN TYPE 2; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BALLOON CATHETER; BLOOD SAMPLING; BLOOD VESSEL INJURY; CHOLESTEROL DIET; CONTROLLED STUDY; HYPERCHOLESTEROLEMIA; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NONHUMAN; PROBABILITY; RABBIT; SMOOTH MUSCLE FIBER; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 44449173719     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-6-4     Document Type: Article

References (34)

1. Wilson AJ Vascular hyper-reactivity following arterial balloon injury: distant and delayed effects Br J Pharmacol 2004, 142:3-4 Comentary 1574924 15037512 10.1038/sj.bjp.0705734
2. Accorsi-Mendonça D Corrêa FMA Paiva TB De Souza HP Laurindo FRM De Oliveira AM The balloon catheter induces an increase in contralateral carotid artery reactivity to angiotensin II and phenylephrine Br J Pharmacol 2004, 142:79-88 1574923 15037520 10.1038/ sj.bjp.0705732
3. Hansson GK Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 2005, 352(16):1685-95 10.1056/NEJMra043430 15843671
4. Hsueh WA Jackson S Law RE Control of vascular cell proliferation and migration by PPAR-γ Diabetes Care 2001, 24:392-397 10.2337/ diacare.24.2.392 11213897
5. Hennuyer N Tailleux A Torpier G Mezdour H Fruchart JC Staels B Fiévet C PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia Arterioscler Thromb Vasc Biol 2005, 25:1897-1902 10.1161/01.ATV.0000175756.56818.ee 15994444
6. Phillips JW Barringhaus KG Sanders JM Yang Z Chen M Hesselbacher S Czarnik AC Ley K Nadler J Sarembock IJ Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes Circulation 2003, 108:1994-1999 10.1161/ 01.CIR.0000092886.52404.50 14517165
7. Levi Z Shaish A Yacov N Levkovitz H Trestman S Gerber Y Cohen H Dvir A Rhachmani R Ravid M Harats D Rosiglitazone (PPARγ-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes- atherosclerosis mouse model Diabetes Obes Metab 2003, 5(1):45-50 10.1046/j.1463-1326.2003.00240.x 12542724
8. Tao L Liu HR Gao E Teng ZP Lopez BL Christopher TA Ma XL Batinic-Haberle I Willette RN Ohlstein EH Yue TL Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia Circulation 108, 22:2805-11 2003 Dec 2 10.1161/01.CIR.0000097003.49585.5E 14610009
9. Taskiran D Taskiran E Yercan H Kutay FZ Quantification of total collagen in rabbit tendon by the Sirius red method Tr J of Medical Scienses 1999, 29:7-9
10. Stary HC Blankenhorn DH Chandler AB Glagov S Insull W Jr Richardson M Rosenfeld ME Schaffer SA Schwartz CJ Wagner WD A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association Circulation 1992, 85(1):391-405 Review 1728483
11. Stary HC Chandler AB Glagov S Guyton JR Insull W Jr Rosenfeld ME Schaffer SA Schwartz CJ Wagner WD Wissler RW A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association Circulation 1994, 89(5):2462-78 Review 8181179
12. Stary HC Chandler AB Dinsmore RE Fuster V Glagov S Insull W Jr Rosenfeld ME Schwartz CJ Wagner WD Wissler RW A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association Circulation 1995, 92(5):355-74 Review
13. Zhao-hui W Feng L Xiao-mei L Effect of PPARγ agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits Yao Xue Xue Bao 2005, 40(11):1051-1053 16499094
14. Li AC Brown KK Silvestre MJ Willson TM Palinski W Glass CK Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J Clin Invest 2000, 106(4):523-31 380255 10953027 10.1172/JCI10370
15. Li AC Binder CJ Gutierrez A Brown KK Plotkin CR Pattison JW Valledor AF Davis RA Willson TM Witztum JL Palinski W Glass CK Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ J Clin Invest 2004, 114:1564-1576 529277 15578089
16. Collins AR Meehan WP Kintscher U Jackson S Wakino S Noh G Palinski W Hsueh WA Law RE Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice Arterioscler Thromb Vasc Biol 2001, 21:365-371 11231915
17. Chawla A Boisvert WA Lee CH Laffitte BA Barak Y Joseph SB Liao D Nagy L Edwards PA Curtiss LK Evans RM Tontonoz P A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis Mol Cell 2001, 7(1):161-71 10.1016/S1097-2765(01)00164-2 11172721
18. Chinetti G Lestavel S Bocher V Remaley AT Neve B Torra IP Teissier E Minnich A Jaye M Duverger N Brewer HB Fruchart JC Clavey V Staels B PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway Nat Med 2001, 7(1):53-8 10.1038/83348 11135616
19. Ricote M Huang J Fajas L Li A Welch J Najib J Witzum JL Auwerx J Palinski W Glass CK Expression of the peroxisome proliferator-activated receptor-γ (PPAR-γ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein Proc Natl Acad Sci USA 1998, 95:7614-7619 22700 9636198 10.1073/pnas.95.13.7614
20. Tontonotz P Nagy L Alavarez JGA Thomazy VA Evans RM PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 1998, 93:241-252 10.1016/S0092-8674(00)81575-5 9568716
21. Panunti B Fonseca V Effects of PPAR gama agonists on cardiovascular function in obese, nondiabetic patients Vasc Pharmacology 2006, 45:29-35 10.1016/j.vph.2005.11.013
22. Reidy MA Proliferation of smooth muscle cells at sites distant from vascular injury Arteriosclerosis 1990, 10(2):298-305 2317164
23. Seki N Bujo H Jiang M Shibasaki M Takahashi K Hashimoto N Saito Y A potent activator of PPARα and γ reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits Atherosclerosis 2005, 178:1-7 10.1016/ j.atherosclerosis.2004.08.015 15585194
24. Marx N Schonbeck U Lazar MA Libby P Plutzky J Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells Circ Res 1998, 83(11):1097-1103 9831704
25. Marx N Froehlich J Siam L Ittner J Wierse G Schmidt A Scharnagl H Hombach V Koenig W Antidiabetic PPAR-γ activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease Arterioscler Thromb Vasc Biol 2003, 23:283-288 10.1161/ 01.ATV.0000054195.35121.5E 12588772
26. Sugawa A Kazuhisa T Uruno A Ikeda Y Arima S Masataka K Sato K Taniyama Y Ito S Transcriptional suppresion of type I angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells Endocrinology 2001, 142(7):3125-3134 10.1210/en.142.7.3125 11416035
27. Wakino S Kintscher U Kim S Yin F Hsueh WA Law RE Peroxisome proliferator-activated receptor ligands inhibit retinoblastoma phosphorilation and G1- S transition in vascular smooth muscle cells J Biol Chem 2000 ,275(29):22435-22441 10.1074/jbc.M910452199 10801895
28. Murthy SN Obregon DF Chattergoon NN Fonseca NA Mondal D Dunne JB Diez JG Jeter Junior JR Kadowitz PJ Agrawal KC McNamara DB Fonseca VA Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Spague-Dawley rats fed a high methionine diet Metabolism 2005, 54(5):645-652 10.1016/ j.metabol.2004.12.008 15877295
29. Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007, 356:2457-2471 10.1056/NEJMoa072761 17517853
30. Patel CB De Lemos JA Wyne KL Mcguire DK Thiazolidinediones and risk for atherosclerosis: Pleiotropic effects of PPARγ agonism Diab Vasc Dis Res 2006, 3(2):65-71 10.3132/dvdr.2006.016 17058625
31. Home PD Pocock SJ Beckk-Nielsen H Gomis R Hanefeld M Joses NP Komajda M McMurray JJV the Record Study Group Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis N Engl J Med 2007, 357:28-38 10.1056/NEJMoa073394 17551159
32. Singh S Loke YH Furberg CD Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis JAMA 2007, 298:1216-8 10.1001/ jama.298.10.1216 17848659
33. Lipscombe LL Gomes T Lévesque LE Hux JE Juurlink DN Alter DA Thiazolidinediones and cardiovascular outcomes in older patients with diabetes JAMA 2007, 298(10):1189-95 10.1001/jama.298.10.1189 17848653
34. Barbier O Torra IP Duguay Y Blanquart C Fruchart JC Glineur C Staels B Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis Arterioscler Thromb Vasc Biol 2002, 22:717-726 10.1161/01.ATV.0000015598.86369.04 12006382